CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues	$ 6,352	$ 6,590
Costs and expenses:
Cost of goods sold	1,401	1,424
Research and development expenses	1,447	1,178
Acquired in-process research and development expenses	481	8
In-process research and development impairment	0	2,700
Selling, general and administrative expenses	1,319	1,083
Total costs and expenses	4,647	6,393
Operating income	1,705	197
Interest expense	(230)	(238)
Other income (expense), net	(174)	(111)
Income (loss) before income taxes	1,300	(152)
Income tax benefit (expense)	(316)	164
Net income	985	12
Net loss attributable to noncontrolling interest	26	7
Net income attributable to Gilead	$ 1,010	$ 19
Basic earnings per share attributable to Gilead (in dollars per share)	$ 0.81	$ 0.02
Shares used in basic earnings per share attributable to Gilead calculation (in shares)	1,248	1,255
Diluted earnings per share attributable to Gilead (in dollars per share)	$ 0.80	$ 0.02
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)	1,261	1,262
Product sales
Revenues:
Total revenues	$ 6,306	$ 6,534
Royalty, contract and other revenues
Revenues:
Total revenues	$ 46	$ 56